This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.


Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1dic

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 4: Line 4:
==Overview==
==Overview==
-
Factor D (D) is a serine protease essential in the activation of the, alternative complement pathway. Only a few of the common serine protease, inhibitors inhibit D, binding covalently to the serine hydroxyl of the, catalytic triad. 3,4-Dichloroisocoumarin (DCI) is a mechanism-based, inhibitor which inhibits most serine proteases and many esterases, including D. The structure of the enzyme:inhibitor covalent adduct of D, with DCI, DCI:D, to a resolution of 1.8 A is described, which represents, the first structural analysis of D with a mechanism-based inhibitor. The, side chain of the ring-opened DCI moiety of the protein adduct undergoes, chemical modification in the buffered solution, resulting in the formation, of an alpha-hydroxy acid moiety through the nucleophilic substitution of, both Cl atoms. The inhibited enzyme is similar in overall structure to the, native enzyme, as well as to a variety of isocoumarin-inhibited trypsin, and porcine pancreatic elastase (PPE) structures, yet notable differences, are observed in the active site and binding mode of these small-molecule, inhibitors. One region of the active site (residues 189-195) is relatively, conserved between factor D, trypsin, and elastase with respect to, amino-acid sequence and to conformation. Another region (residues 214-220), reflects the amino-acid substitutions and conformational flexibility, between these enzymes. The carbonyl O atom of the DCI moiety was found to, be oriented away from the oxyanion hole, which greatly contributes to the, stability of the DCI:D adduct. The comparisons of the active sites between, native factor D, DCI-inhibited factor D, and various inhibited trypsin and, elastase (PPE) molecules are providing the chemical bases directing our, design of novel, small-molecule pharmaceutical agents capable of, modulating the alternative complement pathway.
+
Factor D (D) is a serine protease essential in the activation of the alternative complement pathway. Only a few of the common serine protease inhibitors inhibit D, binding covalently to the serine hydroxyl of the catalytic triad. 3,4-Dichloroisocoumarin (DCI) is a mechanism-based inhibitor which inhibits most serine proteases and many esterases, including D. The structure of the enzyme:inhibitor covalent adduct of D with DCI, DCI:D, to a resolution of 1.8 A is described, which represents the first structural analysis of D with a mechanism-based inhibitor. The side chain of the ring-opened DCI moiety of the protein adduct undergoes chemical modification in the buffered solution, resulting in the formation of an alpha-hydroxy acid moiety through the nucleophilic substitution of both Cl atoms. The inhibited enzyme is similar in overall structure to the native enzyme, as well as to a variety of isocoumarin-inhibited trypsin and porcine pancreatic elastase (PPE) structures, yet notable differences are observed in the active site and binding mode of these small-molecule inhibitors. One region of the active site (residues 189-195) is relatively conserved between factor D, trypsin, and elastase with respect to amino-acid sequence and to conformation. Another region (residues 214-220) reflects the amino-acid substitutions and conformational flexibility between these enzymes. The carbonyl O atom of the DCI moiety was found to be oriented away from the oxyanion hole, which greatly contributes to the stability of the DCI:D adduct. The comparisons of the active sites between native factor D, DCI-inhibited factor D, and various inhibited trypsin and elastase (PPE) molecules are providing the chemical bases directing our design of novel, small-molecule pharmaceutical agents capable of modulating the alternative complement pathway.
==Disease==
==Disease==
Line 17: Line 17:
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Single protein]]
-
[[Category: Babu, Y.S.]]
+
[[Category: Babu, Y S.]]
[[Category: Chu, N.]]
[[Category: Chu, N.]]
-
[[Category: Cole, L.B.]]
+
[[Category: Cole, L B.]]
-
[[Category: Kilpatrick, J.M.]]
+
[[Category: Kilpatrick, J M.]]
[[Category: DIC]]
[[Category: DIC]]
[[Category: O]]
[[Category: O]]
Line 28: Line 28:
[[Category: serine protease]]
[[Category: serine protease]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Feb 3 09:35:31 2008''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 12:16:54 2008''

Revision as of 10:16, 21 February 2008


1dic, resolution 1.8Å

Drag the structure with the mouse to rotate

STRUCTURE OF 3,4-DICHLOROISOCOUMARIN-INHIBITED FACTOR D

Contents

Overview

Factor D (D) is a serine protease essential in the activation of the alternative complement pathway. Only a few of the common serine protease inhibitors inhibit D, binding covalently to the serine hydroxyl of the catalytic triad. 3,4-Dichloroisocoumarin (DCI) is a mechanism-based inhibitor which inhibits most serine proteases and many esterases, including D. The structure of the enzyme:inhibitor covalent adduct of D with DCI, DCI:D, to a resolution of 1.8 A is described, which represents the first structural analysis of D with a mechanism-based inhibitor. The side chain of the ring-opened DCI moiety of the protein adduct undergoes chemical modification in the buffered solution, resulting in the formation of an alpha-hydroxy acid moiety through the nucleophilic substitution of both Cl atoms. The inhibited enzyme is similar in overall structure to the native enzyme, as well as to a variety of isocoumarin-inhibited trypsin and porcine pancreatic elastase (PPE) structures, yet notable differences are observed in the active site and binding mode of these small-molecule inhibitors. One region of the active site (residues 189-195) is relatively conserved between factor D, trypsin, and elastase with respect to amino-acid sequence and to conformation. Another region (residues 214-220) reflects the amino-acid substitutions and conformational flexibility between these enzymes. The carbonyl O atom of the DCI moiety was found to be oriented away from the oxyanion hole, which greatly contributes to the stability of the DCI:D adduct. The comparisons of the active sites between native factor D, DCI-inhibited factor D, and various inhibited trypsin and elastase (PPE) molecules are providing the chemical bases directing our design of novel, small-molecule pharmaceutical agents capable of modulating the alternative complement pathway.

Disease

Known diseases associated with this structure: Azoospermia OMIM:[400005], Complement factor D deficiency OMIM:[134350], Corneal fleck dystrophy OMIM:[609414], Properdin deficiency, X-linked OMIM:[300383]

About this Structure

1DIC is a Single protein structure of sequence from Homo sapiens with and as ligands. Active as Complement factor D, with EC number 3.4.21.46 Known structural/functional Site: . Full crystallographic information is available from OCA.

Reference

Structure of 3,4-dichloroisocoumarin-inhibited factor D., Cole LB, Kilpatrick JM, Chu N, Babu YS, Acta Crystallogr D Biol Crystallogr. 1998 Sep 1;54(Pt 5):711-7. PMID:9757085

Page seeded by OCA on Thu Feb 21 12:16:54 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools